Publications by authors named "Lidwien Smabers"
Background: Despite recent metastatic colorectal cancer (mCRC) therapeutic innovations a comprehensive synthesis of patient outcome and risk-benefit assessment of phase 1/2 trials is missing. The aim of this meta-analysis is to assess efficacy, safety, and trends over time for phase 1 and 2 mCRC trials by examining clinical benefit rate (CBR), overall response rate (ORR), grade 3 or higher adverse events (AE), and discontinuation due to AE.
Methods: The PRISMA guidelines were followed.
Article Synopsis
- Human cells can trigger a form of programmed cell death (apoptosis) when faced with DNA damage, primarily through the activation of the p53 protein.
- Interestingly, even cells without p53 can still undergo apoptosis, which seems to be linked to issues with protein translation, specifically ribosomes stalling on rare codons and reduced translation initiation.
- A genetic study revealed that the tRNAse SLFN11 and the kinase GCN2 are crucial for this stalling and subsequent stress signaling, which leads to apoptosis, offering insights into chemotherapy resistance in certain tumors where SLFN11 is often inactive.
Article Synopsis
- FBXW7 is a protein that helps break down other proteins, and when it's mutated, it can contribute to cancer.
- Scientists used a special tool called CRISPR to change certain parts of this protein in colon tissue samples, which made the samples grow better without needing as much EGF, a growth factor.
- The research showed that these mutations help keep another protein called EGFR alive longer, making the cancer cells less sensitive to certain treatments.
Background: The inability to predict treatment response of colorectal cancer patients results in unnecessary toxicity, decreased efficacy and survival. Response testing on patient-derived organoids (PDOs) is a promising biomarker for treatment efficacy. The aim of this study is to optimize PDO drug screening methods for correlation with patient response and explore the potential to predict responses to standard chemotherapies.
View Article and Find Full Text PDFBackground: Predicting prognosis in refractory metastatic colorectal cancer (mCRC) patients is needed to guide decision making. The Colon Life nomogram was developed to predict 12-week mortality in refractory mCRC patients. The aim of this study is to validate the Colon Life nomogram in last line/refractory patients receiving trifluridine/tipiracil (FTD/TPI) in daily practice.
View Article and Find Full Text PDF